Author

Amy Williams

Institution: Biovica (Sweden)

Observed institution: Biovica (Sweden)

ORCID: 0009-0000-1359-8222

Observed ORCID: 0009-0000-1359-8222

OpenAlex ID: A5140542620

Supplementary Tables and Figures S1 from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Data from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Protocol 1 from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al. · Clinical Cancer Research

Works count: 4

Citation count:

H-index:

I10-index: